The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RIGL | +115.85% | +13.52% | +2.57% | -95% |
| S&P | +19.61% | +98.99% | +14.75% | +411% |
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
More data is needed.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $101.69M | 176.0% |
| Gross Profit | $97.18M | 185.5% |
| Gross Margin | 95.57% | 3.2% |
| Market Cap | $334.75M | 131.9% |
| Market Cap / Employee | $2.04M | 0.0% |
| Employees | 164 | 11.6% |
| Net Income | $59.61M | 5887.7% |
| EBITDA | $61.71M | 5721.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $53.41M | 48.1% |
| Accounts Receivable | $39.91M | 38.1% |
| Inventory | 10.4 | 1.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $38.17M | -36.1% |
| Short Term Debt | $22.88M | 3480.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 58.38% | 70.0% |
| Return On Invested Capital | -74.57% | 22.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $30.54M | 10011.6% |
| Operating Free Cash Flow | $30.54M | 10011.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 74.70 | 17.31 | 8.68 | 3.46 | - |
| Price to Book | -19.47 | -20.24 | 96.90 | 18.02 | -495.90% |
| Price to Sales | 1.81 | 1.69 | 1.61 | 1.27 | 14.69% |
| Price to Tangible Book Value | -6.73 | -7.00 | -13.38 | -42.12 | 1668.35% |
| Price to Free Cash Flow TTM | 26.64 | 9.62 | 9.19 | 5.17 | - |
| Enterprise Value to EBITDA | 19.41 | 16.52 | 23.24 | 4.75 | -96.76% |
| Free Cash Flow Yield | 3.8% | 10.4% | 10.9% | 19.3% | - |
| Return on Equity | 376.1% | - | |||
| Total Debt | $60.23M | $59.97M | $61.07M | $61.04M | 1.18% |
RIGL earnings call for the period ending September 30, 2020.
RIGL earnings call for the period ending June 30, 2020.
RIGL earnings call for the period ending March 31, 2020.
RIGL earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
